|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00064428 |
The purpose of this research study is to determine the efficacy and safety of fondaparinux (Arixtra) in preventing death and repeat heart attacks and their complications.
Condition | Intervention | Phase |
Myocardial Infarction |
Drug: fondaparinux sodium Drug: heparin Drug: Glucose-insulin-potassium (GIK) |
Phase III |
MedlinePlus related topics: | Heart Attack |
ChemIDplus related topics: | Insulin Fondaparinux sodium ORG 31540 Heparin Dextrose Potassium chloride |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy Trial Evaluating Fondaparinux Use in a Broad Range of Patients With ST Segment Elevation Acute MI |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Show 384 Study Locations |
Sanofi-Aventis |
Study ID Numbers: | EFC5112, SR90107 |
First Received: | July 8, 2003 |
Last Updated: | September 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00064428 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|